REFERENCES
- Murphy R, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 200115:F1—F9.
- Johnson M, Beall G, Badley A, et al. ABT-378/ritonavir versus nelfinavir in antiretroviral naive subjects: week 48 comparison in a phase III blinded randomised clinical trial (study 863). AIDS. 2000;14\(suppl 4):7.
- Hsu A, Granneman G, Kempf D, et al. The Ctrough inhibitory quotient predicts virologic response to ABT-378/ritonavir therapy in treatment experienced patients. AIDS. 2000;14\(suppl 4):12.
- Benson C, Deeks S, Brun S, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritoanvir plus nevirapine and 2 NRTI in HIV-1-infected protease inhibitor-experi-enced patients. J Infect Dis. 2002;185:599–607.
- Rockstroh J, Brun S, Sylte J, et al. ABT-378/ritonavir and efavirenz: one year safety/efficacy evaluation in multiple Pl-experienced patients (study 957). AIDS. 2000;14\(suppl 4):29.
- Clumeck N, Brun S, Sylte J, et al. Kaletra and efavirenz: one year safety/efficacy evaluation and phenotypic breakpoints in multiple P1-experienced patients. In: Pro-gram and abstracts of Eighth Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL. Abstract 525.
- Collins M, Irvine B, Tyner D, et al. A branched DNA signal amplification assay for quantitation of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res. 1997;25: 2979–2984.
- The National Cholesterol Education Program. Treatment of high blood cholesterol in adults. JAMA. 2001;285:2486–2497.
- Kempf D, Isaacson J, King M, et al. Genotypic correlates of reduced in vitro susceptibility to ABT-378 in HIV isolates from patients failing protease inhibitor therapy. In: Program and abstracts of the Fourth International Workshop on HIV Drug Resistance and Treatment Strategies; June 2000; Sitges. Abstract 38.
- International AIDS Society-USA Panel. Antiretroviral resis-tance mutations. Revised April 2001. HIV Clin Trials. 2001;2:346–355.
- Reitmayer R, Rode R, Bernstein B, et al. Initial efficacy results from the Kaletra early access program. In: Program and abstracts of Eighth Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL. Ab-stract 328.
- Harris M, Stewart W, Larsen G, Harrigan R, Montaner J. Response to lopinavir-based multidrug rescue regimens. AIDS. 2000;14\(suppl 4):22.
- Day J, Uriel A, Daintith R, et al. Evaluation of ABT-378/ ritonavir based salvage regimens in a cohort of HIV-in-fected patients. AIDS. 2000;14\(suppl 4):29.
- Calvez V, Cohen-Codar I, Marcelin A, et al. Identification of individual mutations in HIV protease associated with viro-logical response to lopinavir/ritonavir therapy. Antiviral Ther. 2001;6\(suppl 1):40.
- Calvez V, Cohen-Codar I, Marcelin A, et al. Analysis of the correlation between baseline genotypic profile and viro-logical response to lopinavir/ritonavir in 104 multiple P1-experienced patients treated under the expanded access program. Antiviral Ther. 2001;6\(suppl 1):69.
- Masquelier B, Lawson-Ayayi S, Neau D, et al. HIV-1 geno-typic determinants of the virologic response to lopinavir/ ritonavir-containing therapy in P1-experienced patients. Antiviral Ther. 2001;6\(suppl 1):84.